Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

NEW YORK& MAINZ, Germany--(BUSINESS WIRE) May 5, 2020 --Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials